Rocket Pharmaceuticals
RCKT
19 hedge funds and large institutions have $51M invested in Rocket Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
27% more funds holding
Funds holding: 15 → 19 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
3% less capital invested
Capital invested by funds: $52.5M → $51M (-$1.45M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$2.62M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$1.04M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$483K |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
+$387K |
| 5 |
TI
Telemetry Investments
New York
|
+$298K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
-$533K |
| 2 |
PVI
Pura Vida Investments
New York
|
-$474K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$111K |
| 4 |
Morgan Stanley
New York
|
-$94.4K |
| 5 |
Citigroup
New York
|
-$17.7K |
RCKT Hedge Fund Activity: Q2 2015 in Review
19 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2015, worth a combined $51M — down 2.8% from $52.5M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new RCKT positions and 2 closed out — a net gain of 4 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Jennison Associates, adding an estimated $2.62M. The largest seller was Spark Investment Management, exiting entirely with an estimated $533K sold.
- 19 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2015, up from 15 in Q1 2015.
- Funds reported $51M of Rocket Pharmaceuticals stock for Q2 2015, down 2.8% quarter-over-quarter.
- 6 funds opened new Rocket Pharmaceuticals positions in Q2 2015 and 2 closed out, a net change of +4 holders.
- The largest Rocket Pharmaceuticals buyer in Q2 2015 was Jennison Associates, an estimated $2.62M added.
- The largest Rocket Pharmaceuticals seller in Q2 2015 was Spark Investment Management, an estimated $533K sold.
Based on aggregated 13F filings for Q2 2015.